RxDoctor Payments Data

Joel Eichler, MD

Ophthalmology · Belleville, NJNPI 1326033598

Payments from drug & device makers

$3,438in general payments, 2019–2025

Across 149 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$892
  • AbbVie$489
  • Genentech USA, Inc.$378
  • Novartis$355
  • Astellas Pharma US Inc$303
  • Harrow Eye, LLC$228
  • plus $792 from 13 others

What the payments were for

  • Food & beverage$3,438100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,438 in reported general payments places this provider in the 70th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$3,367,973
Medicare patients
1,059
Services billed
31,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine92$111,641
LumiganBimatoprost128$49,649
Alphagan PBrimonidine Tartrate92$35,714
EyleaAflibercept11$32,346
SimbrinzaBrinzolamide/Brimonidine Tart99$20,146
Brimonidine Tartrate251$16,322
CombiganBrimonidine Tartrate/Timolol42$15,569
Cyclosporine23$13,298
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol72$13,130
Loteprednol Etabonate62$12,015
RhopressaNetarsudil Mesylate32$11,565
RocklatanNetarsudil Mesylat/Latanoprost26$11,252
Prednisolone Acetate205$9,689
ZirganGanciclovir14$6,624
Travoprost46$6,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$489$212,572354 claims
Regeneron Healthcare Solutions, Inc.Eylea$892$32,34611 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$28$22,81758 claims
AlconSimbrinza$12$20,14699 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax$41$16,02373 claims
Bausch & Lomb Americas Inc.Zirgan$171$6,62414 claims
Eyevance Pharmaceuticals LLCTobradex St$52$3,43615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Belleville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →